Lactic Acidosis in Patients With Cancer

Jeanne Held-Warmkessel, MSN, RN, ACNS-BC, AOCN®, and Deena Damsky Dell, MSN, RN-BC, AOCN®, LNC

Lactic acidosis is the most common metabolic acidosis in hospitalized patients—the result from an underlying pathogenic process. To successfully manage lactic acid production, its cause needs to be eliminated. Patients with cancer have many risk factors for developing lactic acidosis, including the cancer diagnosis itself. Patients with lactic acidosis are critically ill, requiring an intense level of nursing care with accompanying frequent cardiopulmonary and renal assessments. The mortality rate from lactic acidosis is high. Therefore, appropriate nursing interventions may include end-of-life and palliative care.

Lactic acidosis is the most common metabolic acidosis in hospitalized patients, and it is defined as serum lactic acid (LA) levels greater than 5 mmol/L (normal: less than 2 mmol/L) with a serum pH of less than 7.3 (normal: 7.32–7.42) (Emmett, 2013; Martinez-Outschoorn et al., 2013; Ruiz et al., 2011). Critically ill patients with lactic acidosis have a mortality rate greater than 50%; in patients with cancer who have lactic acidosis, the mortality rate increases to more than 80% (Martinez-Outschoorn et al., 2013).

Patients with cancer have many risk factors for developing lactic acidosis, including the diagnosis of cancer itself. The higher rate of glycolysis, the metabolic pathway that converts glucose to pyruvate, is characteristic of cancer. With glycolysis, LA release increases (Dhup, Dadhich, Porporato, & Sonveaux, 2012; Ruiz et al., 2011). The prevailing theory that explains this increase is referred to as the Warburg effect, which states that cancer cells engage in anaerobic metabolism of glucose even when oxygen is present. The Warburg effect is most strongly associated with lymphoma and leukemia (Martinez-Outschoorn, 2013; Ruiz et al., 2011).

Other mechanisms that may contribute to the development of lactic acidosis in patients with cancer are decreased ability to clear lactate from the liver because of the presence of cancer, overproduction of lactate caused by thiamine and/or riboflavin deficiencies, and embolization of the microvasculature by malignant cells (Emmett, 2013; Ruiz et al., 2011). Patients with cancer also are prone to sepsis, which may cause impaired tissue perfusion with anaerobic metabolism (Blomkalns, 2007; Dell, 2014).

Lactate Metabolism

LA is constantly produced by the cytoplasm of almost all of the cells, particularly the red blood, brain, gut, and skin cells. LA is a normal end product of glucose metabolism via the anaerobic glycolytic pathway. When adequate oxygen and nutrition reach the cells, they obtain their needed energy from the glycolic production of pyruvate, the end product of glycolysis. The pyruvate is converted to acetyl coenzyme A (CoA) by the enzyme pyruvate dehydrogenase. Thiamine is needed as a cofactor for this reaction. The acetyl-CoA enters the cell’s mitochondria and joins in the tricarboxylic acid cycle (TAC), or Krebs cycle.

Thirty-six molecules of adenosine triphosphate (ATP) are produced from one molecule of glucose. If no oxygen is available, the TAC cycle does not proceed, and energy is obtained by converting pyruvate to LA by the enzyme lactate dehydrogenase in the presence of nicotinic acid dehydrogenase (NADH). That anaerobic process only produces four molecules of ATP per molecule of glucose, which dramatically decreases the amount of ATP available to cells (Brandis, n.d.; Emmett, 2013; Gunnerson, 2013; Nandwani, Saluja, Yats, & Mehta, 2010; Ruiz et al., 2011) (see Figure 1).

LA is transported by the blood, primarily to the liver (60%–90%) and kidneys (30%), as well as heart and other tissues, where it is metabolized back to glucose (gluconeogenesis) (Brandis, n.d.; Emmett, 2013; Ruiz, 2011). Two molecules of LA produce one molecule of glucose. This process is referred to as the Cori cycle, and normally results in a balance between the production and use of LA (Brandis, n.d.; Emmett, 2013; Nandwani, n.d.; Ruiz, 2011).